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Abstract
Background: It has not been clearly demonstrated whether HIV vaccination can complicate
routine HIV testing. In this report, we describe the laboratory data of two prisoners who received
rgp120 vaccine in a phase III trial underway in Thailand. These data indicate that previous
vaccination may complicate the interpretation of screening HIV diagnostic tests.
Case presentation: The participants were identified from a cohort study on "Health factors
related to HIV-1 and other viral infections among incarcerated people" that was approved by The
Ethical Committee for Research in Human Subjects, Ministry of Public Health, Thailand. HIV
diagnosis was definitively established with serial specimens using multi-screening tests, Western
blot and diagnostic PCR.
Anti-HIV screening tests consistently exhibited either weakly reactive or inconclusive results. The
band patterns of the Western blot analysis corresponded to those found in individuals who
received the rgp120 vaccination. Definite results were established using diagnostic PCR, which
exhibited consistently negative results with follow-up specimens. Such problems in HIV testing are
not easily resolved in the routine clinical setting in Thailand.
Conclusions: These data demonstrate that HIV-1 vaccination interferes with routine diagnostic
tests. Similar cases will not be uncommon in Thailand, where 2,545 people have already participated
in a phase III trial.
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Background
At present, there is only one protective human immuno-
deficiency virus type 1 (HIV-1) vaccine undergoing phase
III trials.[1,2] In 1998, the phase I/II trial was conducted
among 33 injecting drug users in Bangkok, Thailand, us-
ing rgp 120 derived from HIV 1 subtype B (MN). The pre-
liminary data of the phase I/II trials demonstrated
acceptable safety and immunogenicity, with some break-
through infections. Then, a randomized (ratio1: 1), dou-
ble-blind, placebo-controlled phase III trial, using a
bivalent rgp 120 vaccine derived from subtype B (MN)
and subtype E (244), was initiated in March 1999, in
Bangkok, Thailand, with 2,545 injecting drug users. The
final result on the efficacy of this vaccine may be expected
in late 2003. Indeed, almost 100% of vaccinated individ-
ual seroconverted following immunization and devel-
oped a high antibody titer.[3,4] The development of
antibody following vaccination would be predicted to in-
terfere with anti-HIV screening tests but there are few re-
ports describing such complications.[5–7] In the trials,
vaccinated individuals are distinguished from HIV infect-
ed cases by nucleic acid tests such as PCR.[4,8,9] However,
it is questionable whether or not the technique of PCR can
be routinely implemented in the trial sites. [9] In this re-
port, we present data derived from two vaccinated indi-
viduals whose vaccination history was not known before
inconclusive anti-HIV test results were observed. The con-
founding effects of vaccination upon subsequent HIV test-
ing are discussed and recommendations suggested.
Case presentation
Setting
The two cases reported were male prisoners selected from
among 689 participants in a study on health factors relat-
ed to HIV-1 and other viral infections among incarcerated
people. The study was reviewed and approved in 2001 by
The Ethical Review Committee for Research in Human
Subjects, Ministry of Public Health, Thailand. Participants
received a thorough explanation of the study, including
the risks and benefits, and gave signed informed consent
prior to entry into the study. Patients were visited monthly
during the 6-month period of follow-up. At each visit, the
participants were interviewed regarding their risk behav-
iors, received pre-test or post-test counseling and gave
samples for laboratory tests.
Table 1: Laboratory data of KP 548 and KP 667
KP 548 KP 667
Bleeding time (day) * 0 14 28 60 0 14 28 60
EIA1 (index) ** 2.44 1.72 1.92 1.14 0.95 0.99 1.54 0.93
EIA2 (index) *** 1.31 1.03 0.91 0.65 0.09 0.09 0.12 0.11
GPA NR NR NR NR NR NR NR NR
WB pattern
gp 160 1+ 1+ 1+ +/- - - - -
gp 120 4+ 3+ 3+ 3+ +/- 1+ 3+ 2+
P51 +/- - +/- +/- - - - -
gp 41 4+ 3+ 3+ 2+ - - - -
P31 - - - - 2+ 2+ 2+ 2+
Interpretation Pos Pos Pos Pos ID ID ID ID
PCR
DNA-PCR Neg Neg Neg Neg Neg Neg Neg Neg
RT-PCR Neg Neg Neg Neg Neg Neg Neg Neg
day after first visit; ** EIA1, Vironostika, Uni-Form II Ag/Ab ; *** EIA2, Abbott HIV1/2 gr O EIA; GPA, Gel particle agglutination; WB, Western blot; 
Pos, Positive result; Neg, Negative result; NR, non-reactive; index, OD/Cutoff value; ID, Indeterminate result; 1+ to 4+, relative intensities of bands 
in WB as compared to those of weakly reactive control; Interpretation criteria for positive WB was the presence of 2 envelopes +/- gag +/- pol, as 
recommended by the manufacturer.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/19
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Laboratory tests
HIV diagnosis was established by a combination of
screening tests as recommended by the WHO[10] and
Ministry of Public Health, Thailand.[11] HIV-1 antibody
testing was performed with a two enzyme immunoassay
(EIA) using Uni-Form II Ag/Ab (Organon Technika) and
HIV1/2 gr. O EIA (Abbott laboratories) together with a gel
particle agglutination test (GPA, Fugirebio Inc.). Positive
anti-HIV results were reported after concordant reactive
results were observed. In the case of discordant results
from these screening tests, the specimens underwent
Western blot analysis (HIV blot 2.2, Genelabs diagnostic)
and HIV-1 RNA and DNA were detected by in-house PCR
as described in a previous report.[12]
Results
1. Characteristics of the cases
KP 548 and KP 667 were heroin users (by injection) since
1991 (KP 548) and 1994 (KP 667). They had shared nee-
dles before and during incarceration. In addition, KP 667
shared needles with two HIV-infected prisoners. However,
both KP 548 and KP 667 were anti-HIV negative in the lat-
est tests undertaken in 2001.
2. Laboratory data
The results of screening tests on KP 548 and KP 667 were
consistently discordant at the first visit and 2, 8 and 14
weeks later. All specimens were analyzed by Western blot
that demonstrated unique high intensities of gp120 but
Figure 1
Western Blot results of KP 548 and KP667 *Day after first visit. WPC: weak positive control
Day 0 14 28 60 0 14 28 60
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minor or undetectable gp160. Such Western blot banding
patterns were not found in any HIV-1 infected cases. After
analysis of the serial specimens, the serological test results
remained inconclusive and indeterminate Both RT-PCR
and DNA PCR for HIV-1 were consistently negative in all
the samples. The history of vaccination was elicited at the
fourth visit after a 2-month period of follow-up. Detailed
laboratory data is illustrated in Table 1.
Discussion and conclusion
KP548 and KP667 were two out of 2,545 individuals in-
volved in a phase III trial in Thailand. Their clinical speci-
mens were tested for HIV-1 infection using the same test
algorithm used for routine individual diagnostic speci-
men testing. Their vaccination history was not known
since such data was not included in both the question-
naire and the pre-test counseling but was discovered by
the laboratory test results and was confirmed by retrospec-
tive interviewing of the cases. Thus, a vaccination history
should be included in the standard pre-test counseling
both for diagnosis and blood safety. Secondly, the vaccine
induced antibody response can complicate anti-HIV-1
screening tests. Similar complications were observed
among vaccinees in the phase I/II trial. The vaccine had in-
duced antibody that was detectable by EIAs and Western
blot. The extent of reactivity of the tests was depended on
antigenic determinants of the tests and the vaccines.[6,7]
The weakly reactive EIA and discordant screening test re-
sults were similar to those of early seroconverters. Howev-
er, the follow-up testing exhibited stable signals in the EIA
and Western blot, while those of early seroconverters
should be increasing. Thirdly, the Western blot results
were incorrectly reported as anti-HIV positive if the band
intensities were not scored. As demonstrated in Figure 1,
the intensities of gp120 were significantly higher than the
intensities of gp160. Such relative intensities were not ob-
served in any HIV-1 infected cases. Finally, the definite di-
agnosis was obtained after PCR testing of serial
specimens. However, PCR testing is not available or af-
fordable for all laboratories in Thailand, except in the case
of a few research settings. Furthermore, such viral genome
detection test is prone to contamination as demonstrated
in a vaccinee who got repeatedly false positive HIV RT-
PCR.[9] These two cases demonstrate the potential impact
of HIV vaccination on the laboratory diagnosis of HIV in
all places where people have access to HIV vaccines. An-
other complication of HIV vaccine trial is trial-related dis-
crimination that occurred at 5% of the volunteers. Among
these events, 10% was reported to be linked with HIV test-
ing.[5] The design of efficacy trial of new HIV vaccines
should be in parallel with development of novel diagnos-
tic tests that are capable of differentiating between immu-
nization and true HIV infection.
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